contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab-9

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

It has been on my watchlist. The stock crashed a few years ago when two graders had interpreted the same MRI images differently at different points in time. The interpretations had to be redone. The company got into a difficult spiral with financing during the post-covid crash. This is just from memory. But the product is quite niche. Too niche for me. It’s hard to estimate what the market size is, and how good the product really is. Besides, the information on the company’s own website is so scarce / hard to find that I’ll pass.

Like many other companies in the biotech sector, Ascelia has experienced total capitulation in its share price. However, it should be noted that FDA approval is just around the corner, and even though it is a penny stock, that does not in itself dictate the future. Fundamentally, it sounds very interesting if the company can facilitate the detection and treatment of liver metastases.                   ascelia.com              About us – ASCELIA    Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medic ...

Let’s open a thread for this one too. Ascelia is a company from Sweden specializing in cancer diagnostics and treatment. Company page: Ascelia Pharma - Inderes Investment research: https://www.inderes.fi/fi/ascelia-pharma-investment-case-24-march-2022-hc-andersen-capital

Ascelia Pharma

Under april månad har det registrerade antalet aktier och röster i Ascelia Pharma AB (”Ascelia Pharma”) ökat till följd av den riktade nyemissionen av stamaktier som offentliggjordes av Ascelia...

<div class="mfn-body"><p><strong>Under april månad har det registrerade antalet aktier och röster i Ascelia Pharma AB (”Ascelia Pharma”) ökat till följd av den riktade nyemissionen av stamaktier som offentliggjordes av Ascelia Pharma den 23 april 2026. Per den 30 april 2026 uppgår det totala antalet aktier i Ascelia Pharma till 134 569 246 aktier, varav 133 535 460 är stamaktier med en röst vardera och 1 033 786 är C-aktier med en tiondels röst vardera. Det totala antalet röster i Ascelia Pharma uppgår per den 30 april 2026 till 133 638 838,6.</strong></p></div><div class="mfn-footer mfn-7f5eadc7c3d3"><p><strong class="mfn-heading-1">Om oss</strong></p><hr><p>Ascelia Pharma är ett bioteknikbolag fokuserat på behandlingar med särläkemedel inom onkologi. Bolaget utvecklar och kommersialiserar nya läkemedel som tillgodoser medicinska behov och har en tydlig väg framåt rörande utveckling och marknadsföring. Bolaget har två produktkandidater – Orviglance och Oncoral – i utveckling. Ascelia Pharma har sitt huvudkontor i Malmö och är noterat på Nasdaq Stockholm (kortnamn: ACE). För mer information besök&nbsp;<a href="http://www.ascelia.com/" rel="noopener">http://www.ascelia.com</a>.<br><strong><br></strong></p></div><div class="mfn-footer mfn-5c7f03d9b448"><p><strong class="mfn-heading-1">Kontakter</strong></p><hr><p>Magnus Corfitzen, CEO<br>Epost:&nbsp;<a href="mailto:moc@ascelia.com" rel="noopener">moc@ascelia.com</a><br>Tel: +46 735 179&nbsp;118</p><p>Anton Hansson, CFO<br>Email:&nbsp;<a href="mailto:anton.hansson@ascelia.com" rel="noopener">anton.hansson@ascelia.com</a><br>Tel: +46 735 179 113</p><p><em>Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande.</em></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-lhfi"><p><em>Denna information är sådan information som Ascelia Pharma är skyldigt att offentliggöra enligt lagen om handel med finansiella instrument. Informationen lämnades för offentliggörande den 2026-04-30 11:00 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Bifogade filer</strong></p><hr><p><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/2cdb2c87-ef2e-41fd-814c-95587e5719ec/andring-av-antalet-aktier-och-roster-i-ascelia-pharma-ab.pdf" rel="noopener">Ändring av antalet aktier och röster i Ascelia Pharma AB</a></p></div>